AI assistant
Quantum Genomics — Regulatory Filings 2018
Dec 19, 2018
1617_iss_2018-12-19_826314b6-e14a-4cb8-8798-559cfa886798.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Quantum Genomics to Present at Biotech Showcase 2019
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, today announced that it will be presenting at the Biotech Showcase in San Francisco, CA, being held on January 7-9, 2019. Chief Executive Officer of Quantum Genomics, Jean-Philippe Milon, and the Management team, will be giving a presentation and meeting with investors and pharmaceutical companies.
| Event: | Biotech Showcase™ | |
|---|---|---|
| Date | Tuesday, January 8, 2019 | |
| Time: | 3:30 pm PT | |
| Location: | Hilton San Francisco Union Square, San Francisco, CA (Yosemite A) |
For investors attending the Biotech Showcase, please contact Quantum Genomics Investor Relations team to schedule a meeting with management at [email protected].
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on its 20-plus years of basic and clinical research at some of the largest French laboratories: the French National Institute of Health and Medical Research (INSERM), the French National Centre for Scientific Research (CNRS), the Collège de France, and Paris-Descartes University. The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with heart failure dies within five years).
Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).
For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn
Contact information
Quantum Genomics
| Jean-Philippe Milon | Marc Karako |
|---|---|
| CEO | CFO - Investor Relations |
| +33 (0)1 85 34 77 70 [email protected] | +33 (0)1 85 34 77 70 [email protected] |
So Bang (European Investor & Media Contact)
| Edison Advisors (U.S. Investor Contact) | LifeSci Public Relations (U.S. Media Contact) |
|---|---|
| +33 (0)6 88 48 48 02 [email protected] | +33 (0)6 85 82 41 95 [email protected] |
| Media Relations and Scientific Communications | Financial Communications |
| Samuel Beaupain | Nathalie Boumendil |
Joseph Green Investor Relations +1 (646) 653-7030 | [email protected]
Michael Tattory Media Relations and Scientific Communications
+1 (646) 751-4362 | [email protected]